Human Leukocyte Antigen–Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Analysis

Lacerda, Marcelo Pitombeira de; Rodrigues, Celso Arrais; Pereira, Andréa Z; Novis, Yana; Fonseca, Marina; Silva, Roberto L.; Macedo, Maria Cristina Martins de Almeida; Hamerschlak, Nelson; Esteves, Iracema; Filho, Jayr Schmidt; Nascimento, Marina; Rocha, Vanderson

doi:10.1016/j.bbmt.2017.01.079

Cited by 7 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Estimation of PFS and OS at 2 years was 54% and 66%, respectively. The estimated higher NRM compared to other studies is likely from increased infection risk more so than GvHD, which may be a reflection of health care access and socioeconomic limitations [40]. The results were encouraging, however, showing the generalizability of unmanipulated TCR grafts with PTCy in developing countries.…”

Section: Application Of Haplo-hsct For Hlmentioning

confidence: 84%

See 1 more Smart Citation

Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?

Patel

2019

World J Oncol

View full text Add to dashboard Cite

Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide (PTCy) offers universal donor availability and can potentially cure relapsed or primary refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). However, a conditioning regimen intensity that balances the graft-versus-lymphoma (GvL) effect with regimen-related toxicities (RRTs) has not yet been optimized. Limited data exist on the management of relapse, which is common post-transplant. Few prospective or randomized control trials have been conducted on lymphoma patients undergoing haplo-HSCT. Therefore, the current review aims to summarize published retrospective data in the field to help guide clinical decision making for high-risk patients. Retrospective studies in the field are characterized by variability in patient population and sample sizes, eligibility criteria, number of prior treatments (e.g., chemotherapy, radiation therapy, and autologous transplant), graft source (bone marrow or peripheral blood), as well as choice and intensity of the conditioning regimen (non-myeloablative, reduced intensity, or myeloablative). Nonetheless, common themes that emerge from the literature include: 1) Enhanced donor availability and selection with haplo-HSCT with success in heterogeneous patient populations; 2) Outcomes that are comparable if not superior to matched related (MRD) or unrelated (MUD) donor transplants; 3) The benefit of PTCy for reducing incidence of relapse and chronic graft-versus-host disease (GvHD); 4) Presence of co-morbidities leading to poorer transplant-related outcomes; and 5) The need for novel approaches to address disease relapse, particularly for patients with active disease at the time of transplant. Excellent transplant-related outcomes with haplo-HSCT with PTCy have been seen for HL and NHL based on retrospective data. Further studies are needed to determine integration with advanced cellular therapy techniques, such as chimeric antigen receptor (CAR) T-cell, antibody drug conjugates, and checkpoint inhibitors. Graft manipulation may be another avenue for future research.

show abstract

Section: Application Of Haplo-hsct For Hlmentioning

confidence: 84%

“…An advantage of haplo-HSCT with PTCy is donor availability and reproducibility, as shown by Lacerda and colleagues, who retrospectively reviewed outcomes of 24 patients who received RIC regimens in six low resources centers in Brazil [40]. The patients had a median age at transplant of 27.…”

Section: Application Of Haplo-hsct For Hlmentioning

confidence: 99%

Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?

Patel

2019

World J Oncol

View full text Add to dashboard Cite

show abstract

“…However, suitable donors are often not available, and haploidentical transplantation is under investigation for selected cases. Investigators from Brazil retrospectively evaluated 24 patients undergoing haploidentical transplantation for refractory or relapsed HL [ 109 ]. After a median follow-up 30 months, 2-year PFS and OS rates were 54% and 66%, respectively, with a cumulative incidence of non-relapse-related mortality of 26%, usually from infections.…”

Section: Current Prospects and Experience In Brazilmentioning

confidence: 99%

Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability

Xavier,

Farias,

Neto

et al. 2023

Oncotarget

View full text Add to dashboard Cite

Classic Hodgkin lymphoma (CHL), which accounts for 90-95% of all cases of Hodgkin lymphoma, is the most frequent cancer in adolescents and the most frequent lymphoma in adolescents and young adults. Despite progressive improvements over past decades and the general sensitivity of CHL to frontline chemotherapy, approximately 10-15% of patients have refractory disease that either does not respond to such therapy or progresses after an initial partial response. In patients with refractory or relapsed disease, standard treatment until recently consisted mainly of salvage chemotherapy, in many cases followed by high-dose chemotherapy and autologous stem-cell transplantation. However, improved understanding of the pathobiology of CHL, coupled with the introduction of novel agents, has markedly changed the treatment landscape in the past decade. Although refractory or relapsed CHL continues to be challenging, the therapeutic landscape is undergoing profound changes brought about by novel agents, particularly brentuximab vedotin and immunotherapy. In this review, we discuss the most salient treatment options for adult patients with refractory or relapsed CHL, with a special focus on the Brazilian healthcare setting, which is constrained by inherent characteristics of this system. In the attempt to balance efficacy, safety and tolerability, practicing physicians must rely on clinical trials and on results from real-world studies, and use their own point of view and experience, as well as patient characteristics and previous therapy, to make treatment decisions for refractory or relapsed CHL. Oncotarget 978 www.oncotarget.com * According to the German Hodgkin Study Group risk group classification [41].

show abstract

T-Cell Replete Haploidentical Transplantation

Castagna¹,

Bramanti²,

Devillier³

et al. 2019

Hematopoietic Cell Transplantation for Malignant Conditions

View full text Add to dashboard Cite

Human Leukocyte Antigen–Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Analysis

Cited by 7 publications

References 9 publications

Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?

Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?

Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability

T-Cell Replete Haploidentical Transplantation

Contact Info

Product

Resources

About